Modulation and Modeling of Monoclonal Antibody N-Linked Glycosylation in Mammalian Cell Perfusion Reactors

被引:66
作者
Karst, Daniel J. [1 ]
Scibona, Ernesto [1 ]
Serra, Elisa [1 ]
Bielser, Jean-Marc [1 ,2 ]
Souquet, Jonathan [2 ]
Stettler, Matthieu [2 ]
Broly, Herve [2 ]
Soos, Miroslav [1 ,3 ]
Morbidelli, Massimo [1 ]
Villiger, Thomas K. [1 ]
机构
[1] Swiss Fed Inst Technol, Dept Chem & Appl Biosci, Inst Chem & Bioengn, HCI F-129,Vladimir Prelog Weg 1, CH-8093 Zurich, Switzerland
[2] Merck Serono SA, Biotech Proc Sci, ZI B 1809, Corsier Sur Vevey, Switzerland
[3] Univ Chem & Technol, Dept Chem Engn, Tech 3, Prague 16628, Czech Republic
基金
瑞士国家科学基金会;
关键词
N-linked glycosylation; mammalian cell culture; perfusion bioreactor; mathematical model; monoclonal antibody; RECOMBINANT THERAPEUTIC PROTEINS; CHO-CELLS; MATHEMATICAL-MODEL; ERYTHROPOIETIN PRODUCTION; SITE-OCCUPANCY; TIME EVOLUTION; CULTURE; NUCLEOTIDE; QUALITY; DESIGN;
D O I
10.1002/bit.26315
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Mammalian cell perfusion cultures are gaining renewed interest as an alternative to traditional fed-batch processes for the production of therapeutic proteins, such as monoclonal antibodies (mAb). The steady state operation at high viable cell density allows the continuous delivery of antibody product with increased space-time yield and reduced in-process variability of critical product quality attributes (CQA). In particular, the production of a confined mAb N-linked glycosylation pattern has the potential to increase therapeutic efficacy and bioactivity. In this study, we show that accurate control of flow rates, media composition and cell density of a Chinese hamster ovary (CHO) cell perfusion bioreactor allowed the production of a constant glycosylation profile for over 20 days. Steady state was reached after an initial transition phase of 6 days required for the stabilization of extra- and intracellular processes. The possibility to modulate the glycosylation profile was further investigated in a Design of Experiment (DoE), at different viable cell density and media supplement concentrations. This strategy was implemented in a sequential screening approach, where various steady states were achieved sequentially during one culture. It was found that, whereas high ammonia levels reached at high viable cell densities (VCD) values inhibited the processing to complex glycan structures, the supplementation of either galactose, or manganese as well as their synergy significantly increased the proportion of complex forms. The obtained experimental data set was used to compare the reliability of a statistical response surface model (RSM) to a mechanistic model of N-linked glycosylation. The latter outperformed the response surface predictions with respect to its capability and reliability in predicting the system behavior (i.e., glycosylation pattern) outside the experimental space covered by the DoE design used for the model parameter estimation. Therefore, we can conclude that the modulation of glycosylation in a sequential steady state approach in combination with mechanistic model represents an efficient and rational strategy to develop continuous processes with desired N-linked glycosylation patterns. (c) 2017 Wiley Periodicals, Inc.
引用
收藏
页码:1978 / 1990
页数:13
相关论文
共 51 条
[1]   Effect of Culture Temperature on Erythropoietin Production and Glycosylation in a Perfusion Culture of Recombinant CHO Cells [J].
Ahn, Woo Suk ;
Jeon, Jae-Jin ;
Jeong, Yeong-Ran ;
Lee, Seung Joo ;
Yoon, Sung Kwan .
BIOTECHNOLOGY AND BIOENGINEERING, 2008, 101 (06) :1234-1244
[2]   Determination of Chinese hamster ovary cell line stability and recombinant antibody expression during long-term culture [J].
Bailey, Laura A. ;
Hatton, Diane ;
Field, Ray ;
Dickson, Alan J. .
BIOTECHNOLOGY AND BIOENGINEERING, 2012, 109 (08) :2093-2103
[3]   Tailoring Recombinant Protein Quality by Rational Media Design [J].
Bruehlmann, David ;
Jordan, Martin ;
Hemberger, Juergen ;
Sauer, Markus ;
Stettler, Matthieu ;
Broly, Herve .
BIOTECHNOLOGY PROGRESS, 2015, 31 (03) :615-629
[4]   Optimisation of the cellular metabolism of glycosylation for recombinant proteins produced by mammalian cell systems [J].
Butler, M. .
CYTOTECHNOLOGY, 2006, 50 (1-3) :57-76
[5]   The choice of mammalian cell host and possibilities for glycosylation engineering [J].
Butler, Michael ;
Spearman, Maureen .
CURRENT OPINION IN BIOTECHNOLOGY, 2014, 30 :107-112
[6]   A dynamic mathematical model for monoclonal antibody N-linked glycosylation and nucleotide sugar donor transport within a maturing Golgi apparatus [J].
del Val, Ioscani Jimenez ;
Nagy, Judit M. ;
Kontoravdi, Cleo .
BIOTECHNOLOGY PROGRESS, 2011, 27 (06) :1730-1743
[7]   Towards the Implementation of Quality by Design to the Production of Therapeutic Monoclonal Antibodies with Desired Glycosylation Patterns [J].
del Val, Ioscani Jimenez ;
Kontoravdi, Cleo ;
Nagy, Judit M. .
BIOTECHNOLOGY PROGRESS, 2010, 26 (06) :1505-1527
[8]  
Draper N.R., 1998, APPL REGRESSION ANAL, P307
[9]   MEIGO: an open-source software suite based on metaheuristics for global optimization in systems biology and bioinformatics [J].
Egea, Jose A. ;
Henriques, David ;
Cokelaer, Thomas ;
Villaverde, Alejandro F. ;
MacNamara, Aidan ;
Danciu, Diana-Patricia ;
Banga, Julio R. ;
Saez-Rodriguez, Julio .
BMC BIOINFORMATICS, 2014, 15
[10]   Quality attributes of recombinant therapeutic proteins: An assessment of impact on safety and efficacy as part of a quality by design development approach [J].
Eon-Duval, Alex ;
Broly, Herve ;
Gleixner, Ralf .
BIOTECHNOLOGY PROGRESS, 2012, 28 (03) :608-622